Medical oncology and Precision Medicine

All Items

• Co-mutation patterns and survival associations in lung cancer: a comparative analysis of Swedish and global cohorts

  Nicholas Karlowatz, Linda Köhn, Cedric Patthey, Jonas Nilsson, Mikael Johansson

  836-844

• Tools for providing information to patients about high-tech medical resources for treatment of cancer

  Julie Gehl, Tatiana Michel, Erik Rokkones, Soleakhena Ken, Gregor Sersa, Irene Torres-Espallardo, Ester Orlandi, Laura Ridolfi, Nina Schmidt, Ingrid Kruecken, Barbara Leonardi, Margareta Haag, Aurélie Garcin, Anne-Laure Giraudet, Sandrine Lavallé, Colin Patrick Cantwell, Alexander Jorge Cortez, Chiara Marazzi, Roger Olofsson Bagge, Massimiliano Petrini, Francesca Bonifazi, Vincent Bourbonne, Frédéric Courbon, Ibrahim Edhemović, Lisa Licitra, Sergio Roman-Roman, Jean-Yves Blay

  818-835

• Targeted ALK inhibition achieving tumour control in metastatic melanoma: a case report

  Cornelia Schuster, Irja Alida Oppedal , Liv Iren Vinnem, Eirin Lunden Abrahamsson, Torill Myklestad Barrett, Eli Sihn Samdal Steinskog, Hege Elisabeth Giercksky Russnes , Åslaug Helland

  814-817

• Primary treatment and relative survival by stage and age in vaginal carcinoma: a population-based SweGCG study

  Kristina Hellman, Maria Bjurberg, Christer Borgfeldt, Pernilla Dahm Kähler, Angelique Flöter Rådestad, Jenny-Maria Jönsson, Preben Kjølhede, Cecilia Olsson, Camilla Sköld, Katja Stenström Bohlin, Karin Stålberg, Erik Holmberg, Elisabeth Åvall Lundqvist

  805-813

• FIN-EGFR: real-world treatment outcomes by EGFR mutational subtypes in NSCLC in Southern Finland

  Aija Knuuttila, Monica H. Ekblom , Lalli O. Nurmi, Anna Bonin, Eija K. Heikkilä, Maria Silvoniemi

  781-791

• Exceptional response to alpelisib in a heavily pretreated patient with metastatic breast cancer carrying a PIK3CA mutation outside SOLAR-1 eligible mutations: a case report

  Karolina F. Larsson, Annabelle Forsmark, Henrik Fagman, Maja Drakenberg Danese, Maria Kaire, Matilda Liljedahl, Christoffer Vannas

  776-780

• Association between CAR T-cell persistence and improved response to salvage radiotherapy in patients with DLBCL

  Jiaqi Fan, Nadine Kutsch, Jan-Michel Heger, Philipp Gödel, Eva Heger, Henning Gruell, Philipp Linde, Simone Ferdinandus, Johannes Rosenbrock, Hendrik Dapper, Emmanouil Fokas, Peter Borchmann, Christian Baues

  749-757

• Immune-checkpoint inhibitor-induced bullous pemphigoid in patients with metastatic renal cell carcinoma: two case reports and systematic review of the literature

  Panagiotis Filis, Magnus Lindskog, Philip Curman, Natalia Kuzmina, Åsa Krantz, Katerina Chatzidionysiou, Fernanda Costa Svedman, Ioannis Zerdes

  730-736

• Tolerability and adherence to adjuvant abemaciclib in hormone receptor-positive, HER2-negative, node-positive high-risk early breast cancer: a real-world study

  Carl Rosander, Karolina Larsson , Per Karlsson

  713-720

• The Clinical outcomes following pencil beam scanning proton therapy for skull base chordoma and chondrosarcoma: a single-institution experience

  Tomasz Skóra, kamila rawoj´c, Joanna Anioł, Tomasz Banaś, Anna Cepiga, Agnieszka Chrostowska, Adrianna Chudyba, Magdalena Garbacz, Eleonora Góra, Damian Kabat, Emilia Krzywonos , Tomasz Mikołajski , Jadwiga Nowak-Sadzikowska, Anna Patla, Elżbieta Pluta, Antoni Rucinski, Konrad Urbanek, Dominika Wojton-Dziewońska , Mariusz Wszołek, Renata Kopeć, Kamil Kisielewicz

  679-688

• User perceptions of machine learning models as decision support for colorectal cancer multidisciplinary team conferences (AID-SIM-2): a qualitative simulation study

  Karoline Bendix Bräuner, Birgitte Bruun, Claus Anders Bertelsen, Vegar Johansen Dagenborg, Kristina Safir-Hansen, Rasmus Sanko, Ismail Gögenur, Lars Konge

  668-678

• The impact of pazopanib and extremity radiotherapy on transaminase elevations in soft tissue sarcoma

  Bauke H. G. van Riet, Shermarke Hassan, Thomas R. de Wijkerslooth, Tom T. P. Seijkens, Alwin D. R. Huitema, Neeltje Steeghs, Rick L. Haas

  641-651

• Cardiotoxicity, survival, and dexrazoxane use in patients with soft tissue sarcoma: a Danish population‑based cohort study

  Joanna Vitfell-Rasmussen, Ninna Aggerholm-Pedersen, Christina Brun Knudsen, Kasper Madsen , Lars Fiksen , Niels Junker , Michael Mørk Petersen , Thomas Kümler , Anders Krarup-Hansen , Bodil Elisabeth Engelmann

  590-598

• Overall survival following palliative immune checkpoint inhibitor treatment according to ECOG performance status: a large registry-based study

  Per Nodbrant, Eva Ulff, Magnus Lagerlund, Sander Ellegård, Olle Eriksson, Freddi Lewin, Kristina Engvall

  582-589

• Pathological characteristics and prognosis of very young patients with early breast cancer: a comparative analysis with older patients

  Youri Park, Jin Hoon Nam, Yeonjoo Kwon, Jung Ho Park, Sanghwa Kim, Young Ah Lim, Hee-Joon Kang, Doyil Kim, Janghee Lee

  570-577

• First-in-human quantitative [¹⁵O]H₂O PET imaging of tumour blood flow at rest and during exercise in lymphoma patients

  Milla Perros, Tiia Koivula, Salla Lempiäinen, Tuula Tolvanen, Anna Kirjavainen, Laura Nummijärvi, Carl-Johan Sundberg, Helene Rundqvist, Heikki Minn, Kari Kalliokoski, Ilkka H.A Heinonen

  561-569

• Detection of disease recurrence in real-world patients with completely resected stage III cutaneous melanoma

  Tiina Peuranheimo, Anni Hellman, Siru Mäkelä, Kalle E Mattila, Micaela Hernberg

  535-542

• Oncological outcome and immune-checkpoint-blockade-induced toxicities in patients with cervical cancer – a Norwegian real-world cohort

  Katharina Bischof , Keira Matallah Fredriksen, Margrethe Bjørnstad, Mari Bunkholt Elstrand, Brynhildur Eyjolfsdottir, Alda Birgisdottir, Elisabeth Lillo, Guro Aune, Kristina Lindemann

  518-524

• Long-term lifestyle effects of prehabilitation in colorectal cancer

  Lisa D Geomini, Barend J Spanninga, Margot HM Heijmans, Gerrit D Slooter

  485-492

• Exploring the somatic mutational landscape of ovarian cancer in Estonia

  Mikk Tooming, Kadri Rekker, Kadri Toome, Laura Roht, Piret Laidre, Olga Fjodorova, Ustina Šamarina, Sander Pajusalu, Mihkel Ilisson, Pilleriin Peets, Tõnu Jõgi, Karin Klaup, Kristiina Ojamaa, Eva-Maria Niine-Roolaht, Piret Kaarde, Elen Vettus, Jüri Piirsoo, Helen Vahar, Katrin Õunap, Tiina Kahre

  422-429

• Real-world outcomes of pembrolizumab in advanced anal cancer: a nationwide Danish anal Cancer Group report

  Karen-Lise Garm Spindler, Christian Andreas Hvid, Lars Ulrik Fokdal, Karen Lycke Wind, Anne Vittrup Jakobsen, Rikke Løvendahl Eefsen, Eva Serup-Hansen

  394-400

• A 10-year-long ongoing complete response to vismodegib as first-line treatment in adult metastatic medulloblastoma

  Suweydo Abdi, Paula Poikonen-Saksela, Päivi Halonen, Olli Tynninen, David A Reardon, Micaela Hernberg

  412-415

• PIK3CA mutation testing and alpelisib use in metastatic breast cancer: a real-world data set

  Maja B Drakenberg Danese, Christoffer P Vannas, Henrik A Fagman, Per O Karlsson, Karolina F Larsson

  401-405

• Tumour acquisition method and molecular profiling success in advanced cholangiocarcinoma

  Eleni Vrana, Alia Alothman, Luke Taylor, Joe Geraghty, Javaid Iqbal, Lucy Foster, Alicia-Marie Conway, Nadina Tinsley, Melissa Frizziero, Victoria Foy, Richard A Hubner, Mairéad G McNamara

  389-393

• Incidence and impact of pseudoprogression and mixed responses in metastatic renal cell carcinoma patients treated with ipilimumab/nivolumab: a retrospective analysis

  Aaron Caeyman, Giulia Mammone, Lisa Kinget, Marcella Baldewijns, Liesbeth De Wever, Maarten Albersen, Philip R Debruyne, Octavie Demeulenaere, Edward Scott McTaggart, Saurabh Saraswat, Charlien Berghen, Gert De Meerleer, Stefan Naulaerts, Abhishek D Garg, Benoit Beuselinck

  379-388

• SPRINTR: Swedish PRecision medicine Initiative for Novel Treatments and Research-towards efficient recruitment to clinical trials for prostate cancer

  Karin Welén, Andreas Josefsson

  375-378

• Adenocarcinoma of the small intestine cohort: prospectively collecting real-world data to improve care and quality of life for patients with a rare cancer

  Pascale J.M. Schafrat, Tim R. de Back, Felice N. van Erning, Frederieke H. van der Baan, Geraldine R. Vink, Miriam Koopman, Ruben S.A. Goedegebuure, Louis Vermeulen, Ignace H.J.T. de Hingh, Dirkje W. Sommeijer

  363-369

• Treatment of neuropathic pain in cancer survivors: a scoping review of pharmacological, exercise, and psychosocial interventions

  Ellen Lund Schaldemose, Bolette Skjødt Rafn, Pernille Envold Bidstrup, Agon Olloni, Katrin Schättiger, Peter Christensen, Cæcilie Borregaard Myrhøj, Maja Johannsen Lindberg, Christoffer Johansen, Sandra Jensen, Ida Hovdenak, Sasja Jul Håkonsen, Lise Ventzel

  333-343

• The role of radiotherapy in patients with advanced melanoma failing targeted therapy

  Ellen Heurlin, Lina Grödeberg, Hildur Helgadottir

  344-354

• Multidisciplinary team meetings for lung cancer in the Nordic countries: results from a Nordic survey

  Anja Gouliaev, Janna Berg, Johan Isaksson, Heidi Andersén, Torben Riis Rasmussen

  301-305

• FOCU.SE trial: a nationwide Swedish drug repurposing protocol and research framework

  Edvard Abel, Päivi Östling, Ebba Hallersjö Hult, Katarzyna Kulbacka, Haris Babacic, Annika Baan, Ana Carneiro, Luigi De Petris, Henrik Fagman, Signe Friesland, Oskar Frisell, Mats Hellström, Gabriel Lindahl, Katarina Steen Carlsson, David Tamborero, Antonios Valachis, Daniel Öhlund, Janne Lehtiö, Richard Rosenquist, Anders Edsjö

  268-272

• Targeted therapy in the treatment of lung cancer in Iceland 2010–2023

  Stefanía Ásta Tryggvadóttir, Guðlaugur V. Stefánsson, Helgi Birgisson, Örvar Gunnarsson, Tómas Guðbjartsson, Hrönn Harðardóttir, Bylgja Hilmarsdóttir, Rósa B. Barkardóttir, Sigurdis Haraldsdottir

  261-267

• Prevalence and risk factors for nausea and vomiting in breast cancer patients undergoing chemotherapy

  Yuhui Feng, Liushan Wei, Qinhong Zou, Xiaoyong Lei, Xiaoyan Yang

  252-260

• How does pulmonary function impact QoL in patients with locally advanced NSCLC treated with chemoradiotherapy and durvalumab?

  Frigg Å. Sommervoll, Henrik Horndalsveen , Dag Einar Sommervoll, Jussi Koivonen, Tarje Onsøien Halvorsen, Bjørn Henning Grønberg, Marianne Aanerud, Saulius Cicenas, Nina Helbekkmo, Jarkko Ahvonen, Maria Silvoniemi, Gina Barrera, Maria M. Bjaanæs, Vilde Haakensen, Åsa Öjlert, Kersti Oselin, Åslaug Helland, Tesfaye Madebo

  232-240

• Merging clinical research and standard healthcare – Nordic Precision Cancer Medicine Symposium 2025

  Elisa Bjørgo, Nina Ånensen, Gro Live Fagereng, Hege G. Russnes, Sigbjørn Smeland, Kjetil Taskén, Åslaug Helland

  181-185

• ‘Crossing borders’ in data standardisation: application of OMOP CDM in an international clinical trial network in precision cancer medicine

  Maria Martin Agudo, Henk van der Pol, Gabriel Bratseth Stav, Tina Kringelbach , Katarina Puco, Åsmund Flobak, Hans Gelderblom, Kjetil Taskén, Gro Live Fagereng, Eivind Hovig

  159-163

• Realising precision oncology through shared real-world data infrastructure

  Andreas Bjerrum, Andreas Fanø, Ulrik Lassen

  156-158

• FIN-EGFRprint: a Finnish real-world study on treatments and outcomes in advanced NSCLC with common EGFR mutations

  Aija Knuuttila, Lalli O Nurmi, Petri M Vänni, Eija K Heikkilä, Joanne Edwards, Monica H Ekblom, Irene Luccarini, Maria Silvoniemi

  119-125

• Real-world outcome of neoadjuvant therapy with or without pembrolizumab for triple-negative breast cancer

  Meeri Maunu, Juho Lähteenmaa, Peeter Karihtala, Suvi Tuohinen, Joonas Laaksolilja, Anders Ståhls, Tuomo Meretoja, Johanna Mattson

  131-140

• A conceptual health economic modelling framework to assess the cost-effectiveness of molecular target–driven treatment regimens in oncology

  Oskar Frisell, Eline Aas, Pia Sofie Henkel, Gro Live Fagereng, Kjetil Taskén, Ebba Hallersjö Hult, Peter Lindgren, Katarina Steen Carlsson

  141-147

• SWE-NEO: Swedish NEO-adjuvant trial comparing anti-PD-1 monotherapy to combined anti-CTLA-4/anti-PD-1 blockade in resectable stage III melanoma: study protocol for a phase III open-label multi-centre trial

  Hildur Helgadottir, Ana Carneiro, Francesca Portelli, Konstantinos Papadakis, Karl Björkström, Muyi Yang, Iva Johansson, Ingela Skogvall Svensson, Allan Jazrawi, Amanda Hallgren, Katja Harbst, Rusana Bark, Suzanne Egyhazi Brage, Anders Berglund, Karolin Isaksson, Stina Wickström, Jonas Nilsson, Lars Ny, Göran Jönsson, Roger Olofsson Bagge

  126-130

• Antibiotic treatment indicates shorter survival in patients with immunotherapy for metastatic kidney cancer

  Elisa Kankkunen, Kaisa Sunela, Timo Makkonen, Katriina Jalkanen, Kalle E Mattila

  83-89

• Clinical outcomes of genomically guided trametinib monotherapy across cancer types: results from the IMPRESS-Norway trial

  Kathinka Schmidt Slørdahl, Katarina Puco, Ragnhild Sørum Falk, Ingrid Dyvik, Sigmund Brabrand, Pitt Niehusmann, Eli Sihn Samdal Steinskog, Egil S. Blix, Åsmund Flobak, Irja Alida Oppedal, Sebastian Meltzer, Cecilie Fredvik Torkildsen, Hanne Blakstad, Kristina Lindemann, Sigbjørn Smeland, Anita Amundsen, Kjetil Taskén , Åslaug Helland

  90-96

• Eribulin-induced resolution of high-risk basal cell carcinoma: implications for microtubule-targeting agents in BCC management: a case report

  Jan Lapins, Niki Radros, Karina Schultz, Ismini Vassilaki, Christina Linder Stragliotto, Hildur Helgadottir

  32-35

• Cost-effectiveness analysis of operative versus non-operative management of colorectal cancer metastases in the Finnish RAXO Study

  Joel Kontiainen, Kaisa Lehtomäki, Timo Muhonen, Jarmo Hahl, Iiro Toppila, Tuija Poussa, Emerik Osterlund, Eetu Heervä, Hanna Stedt, Raija Kallio, Päivi Halonen, Arno Nordin, Aki Uutela, Tapio Salminen, Sonja Aho, Maarit Bärlund, Annika Ålgars, Raija Ristamäki, Annamarja Lamminmäki, Bengt Glimelius, Helena Isoniemi, Pia Osterlund

  36-45

• Stakeholders’ experiences with a clinician-led access programme linking evidence generation and reimbursement for precision cancer treatments: the drug access protocol in the Netherlands

  Christine Leopold, Atse H Huisman, Kevin J. G. M. Vlaar, Haiko J Bloemendal, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani

  22-31
• 

  Characteristics, treatment, and outcome of recurrent gastro-oesophageal adeno­carcinoma after perioperative chemotherapy and radical resection

  Anders Christian Larsen, Susy Shim, Lene Bæksgaard, Per Pfeiffer, Marianne Nordsmark, Jan Reiter Sørensen, Rasmus Brøndum, Anne Krejbjerg Motavaf, Morten Ladekarl

  9-18

• Procedures of data merging in precision cancer medicine: the PRIME-ROSE project

  Henk van der Pol, Tina Kringelbach, Maria Martin Agudo, Gabriel Bratseth Stav, Gro Live Fagereng, Marta Fiocco, Ragnhild Sørum Falk, Victoria Homer, Soemeya Haj Mohammad, Hans Timmer, Loic Verlingue, Åslaug Helland, Kristoffer Rohrberg, Ulrik Lassen, Sarah Halford, Katriina Jalkanen, Tanja Juslin, Matthew G Krebs, Julio Oliveira, Edita Baltruskeviciene, Kristiina Ojamaa, Kjetil Taskén, Hans Gelderblom

  1-8

• Predicting neoadjuvant chemotherapy treatment response in hormone- receptor-positive/HER2-negative breast cancer – results from the Swedish SCAN-B population-based cohort

  Niklas Loman, Hani Saghir, Siker Kimbung

  1577-1589

• Prevalence, molecular characterization, and prognosis of c-Met protein overexpression in a real-world cohort of patients with non-squamous non-small cell lung cancer

  Jair Bar, Mona H. Cai, Yookyung Christy Choi, Shobhit Baijal, Weilong Zhao, Alexander Liede, Athan Vasilopoulos, Lisa Roberts-Rapp, Fang Jiang, Archana Simmons, Christine Ratajczak, Shun Lu, Peter J. Ansell, D. Ross Camidge

  1544-1553
• 

  Outcomes for patients with high-risk ER-positive, HER2-negative early-stage breast cancer: a Danish real-world study

  Ida Christine Jacobsen, Tobias Berg, Maj-Britt Jensen, Ann Søegaard Knop

  1531-1539

• Improved therapies, incomplete data: late toxicity after modern classical Hodgkin Lymphoma radiotherapy

  Daniel Molin

  1540-1543
• 

  Real-world outcomes of 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer: the KuPSMALu trial in Eastern Finland

  Okko-Sakari Kääriäinen, Pekka Poutiainen, Heidi Gröhn, Timo Voivalin, Hanna Mussalo, Satu Pukkila, Kirsi Ketola, Päivi Auvinen

  1515-1522

• Radium-223 use and survival by line of treatment in metastatic castration-resistant prostate cancer: a nationwide population-based register study

  Charlotte Alverbratt, Fredrik Sandin, Viktor Kolmbäck, Hans Garmo, Ola Bratt, Ingela Franck Lissbrant

  1391-1403
• 

  Up-regulation of intra-tumour LDLR gene expression is associated with statin treatment and better prostate cancer prognosis

  Kia Eistrup Fonfara, Jacob Fredsøe, Benedicte Parm Ulhøi, Signe Borgquist, Michael Borre, Karina Dalsgaard Sørensen

  1371-1380

• Janus kinase 1 inhibitors for treating immune checkpoint inhibitor-induced enterocolitis – report of two filgotinib-treated cases and literature review

  Henrik Ekedahl, Gudbjörg Sigurjonsdottir, Viktoria Bergqvist, Björn Båtshake, Ana Carneiro, Jan Marsal

  1365-1370

• Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab

  Alaa Kheir, Berglind Johannsdottir, Alexandra Grönn-Weiss, Lisa L Liu, Anders Ullén, Anna Laurell, Annika Håkansson, Ingrida Verbiené, Gustav Ullenhag, Rickard Carlhed, Fernanda Costa Svedman, Magnus Lindskog, Ulrika Harmenberg

  1355-1364

• Real-world survival outcomes of neoadjuvant versus adjuvant chemotherapy in operable triple-negative breast cancer: a propensity score matched registry-based study

  Ali Inan El-Naggar, Andreas Karakatsanis, Antonios Valachis

  1334-1341

• CNN-based prediction using early post-radiotherapy MRI as a proxy for toxicity in the murine head and neck

  Bao Ngoc Huynh, Manish Kakar, Olga Zlygosteva, Inga Solgård Juvkam, Nina Edin, Oliver Tomic, Cecilia Marie Futsaether, Eirik Malinen

  1312-1320

• Complete remission with olaparib in BRIP1-mutated metastatic high-grade pleomorphic sarcoma: case study and literature review – an example of a genomic profiling-based tumor treatment, in a cancer type with high unmet clinical need

  Alexander D.J. Thooft, Sofie Joris, Celine Jacobs, David Creytens, Sylvie Rottey, Brigitte Maes, Philippe Aftimos, Lore Lapeire

  1295-1306

• Predictive factors of oral mucositis in patients with locally recurrent inoperable head and neck cancer treated with boron neutron capture therapy

  Tanja Mälkiä, Hanna Koivunoro, Tiina Seppälä, Leena Kankaanranta, Liisa Porra, Anu Anttonen, Mikko Tenhunen, Heikki Joensuu

  1307-1311

• Pembrolizumab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a multi-institutional DAHANCA cohort study

  Sebastian Søby, Robin Prestwich, Niels Gyldenkerne, Christian Maare, Camilla K Lonkvist, Maria Andersen, Kinga Nowicka-Matus, Anita Gothelf, Trine Tramm, Kasper Toustrup, Simion Mihaela, Danny Ulahannan, Zsuzsanna Iyizoba-Ebozue, Jesper G Eriksen

  1269-1275

• The levels of circulating tumor DNA and inflammatory proteins depict the clinical response in a patient with metastatic undifferentiated pleomorphic sarcoma, a case report

  Christoffer Vannas, Mandy Escobar, Margaréta Tanyasiová, Mathilda Kindeberg Sederblad, Julia Nyström, Tobias Österlund, David Wennergren, Daniel Andersson, Martin Dalin, Åsa Torinsson Naluai, Henrik Fagman, Anders Ståhlberg

  1212-1216

• Precision cancer medicine 2025: some concerns

  Peter Nygren

  1202-1204

• Radiation exposure of breast tissue in lymphoma radiotherapy: a systematic review of breast dose metrics published since 2000

  Hannah Chamberlin, Georgios Ntentas, David J. Cutter, Richard Cowan, Sacha Howell, Christina Hague, John Radford, Sue Astley, Eliana Vasquez Osorio, Marianne Aznar

  1117-1124

• Adverse health outcomes for prostate cancer patients treated with radiotherapy combined with androgen-deprivation therapy: A population-based, controlled study, from Norway

  Mona Nilsson, Anne Holck Storaas, Tom Børge Johannesen, Ylva Maria Gjelsvik, Kirsti Aas, Sophie Dorthea Fosså, Tor Åge Myklebust

  1109-1116

• Validated prediction of xerostomia in a real-world population: a step toward model-guided radiotherapy

  Emmy Dalqvist, Tiziana Rancati, Anna Embring, Gabriella Alexandersson von Döbeln, Ingmar Lax, Signe Friesland, Eva Onjukka

  1087-1094

• Patient-Reported Outcomes as a Tool for Involvement in Metastatic Melanoma Care

  Pernille Christiansen Skovlund, Ditte Minet Karkov, Charlotte Gjørup Pedersen, Annesofie Lunde Jensen

  1053-1060
• 

  Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years?

  Alexander Decruyenaere, Gennigens Christine, Rottey Sylvie, Laenen Annouschka, Emmanuel Seront, Els Everaert, Philip R Debruyne, Heidi Van Den Bulck, Julie Bastin, Verbiest Annelies, Christof Vulsteke, Peter Schatteman, Daisy Luyten, Sandrine Aspeslagh, Nieves Martinez-Chanza, Marlies De Bock, Thomas Meyskens, Jolanda Verheezen, Barbara Brouwers, Benoit Beuselinck

  979-988

• Real-world insights into moderately hypofractionated thoracic radiotherapy in elderly and multimorbid patients with stage II/III NSCLC: a retrospective study

  Helene Kravutske, Sina Mansoorian, Lukas Käsmann, Janina Lehmann, Cedric Richlitzki, Diego Kauffmann-Guerrero, Nina-Sophie Schmidt-Hegemann, Niels Reinmuth, Amanda Tufman, Julien Dinkel, Richard Gaus, Farkhad Manapov, Claus Belka, Chukwuka Eze

  957-965

• Clinical workflow for reirradiation: national consensus recommendations on imaging, treatment planning, dose accumulation, and treatment delivery

  Laura P. Kaplan, Rebecca J. Tobin, Ane Appelt, Eliana Vasquez Osorio, Isak Wahlstedt, Rasmus L. Christiansen, Martin S. Nielsen, Laura A. Rechner, Simon N. Thomsen, Mikkel D. Lund, Kenneth Jensen, Camilla Kronborg, Lone Hoffmann

  946-956

• Outcome of lung cancer surgery and proportion of lung cancer patients eligible for surgery in five Finnish hospitals in 2018, real world study

  Ville Paappanen, Jenny Tikka, Arja Jukkola, Tuula Klaavuniemi, Liisa Sailas, Maria Tengström, Hanne Kuitunen, Teemu Riekkinen, Satu Tiainen, Outi Kuittinen

  909-916

• Acquired angioedema and rituximab-induced acute thrombocytopenia in splenic marginal zone lymphoma

  Odd Terje Brustugun, Erik Waage Nielsen

  868-871

• Risk factors for early mortality and impaired quality of life in oral cavity cancer – head and neck cancer register study

  Teija Nieminen, Morag Tolvi, Tuija Ylä-Kotola, Lasse Lehtonen, Antti Mäkitie, Taru Ilmarinen

  859-867

• Incidence of myocardial ischemia during treatment with capecitabine: a cohort study with Holter recording and cardiac biomarkers

  Anne Dyhl-Polk, Morten Schou, Kirsten K. Vistisen, Anne-Sophie Sillesen, Stig E. Bojesen, Jens Faber, Merete Vaage-Nilsen, Dorte L. Nielsen

  837-847

• How to choose optimal adjuvant therapies for high-risk hormone receptor-positive, HER2-negative breast cancer after chemotherapy?

  Peeter Karihtala

  815-829

• Treatment outcomes and the role of surgery in gestational trophoblastic neoplasia: a population-based cohort study

  Agnes Larsson, Emelie Wallin, Mats Nilsson, Ulrika Joneborg

  807-814

• Synchronous metastases from colorectal cancer. Treatment and long-term survival compared to patients with metachronous metastases: a population-based study from Central Norway 2001–2015

  Per Even Storli, Rachel Genne Dille- Amdam, Gaute Havik Skjerseth, Mads Vikhammer Gran, Tor Åge Myklebust, Jon Erik Grønbech, Erling A. Bringeland

  797-806

• Discrepancies in regional lung cancer multidisciplinary team decisions can be reduced through national consensus meetings

  Anja Gouliaev, Weronika Maria Szejniuk, Joan Fledelius, Hans Henrik Torp Madsen, Rene Horsleben Petersen, Torben Riis Rasmussen

  793-796

• Treatment and outcomes for locally recurrent rectal cancer in Norway

  Ghazwan Al Haidari, Arne M. Solbakken, Linn Merete Åsli, Eva Skovlund, Christine Undseth, Marianne Grønlie Guren

  784-792

• Impact of age and comorbidities on real-world outcomes in advanced breast cancer patients treated with palbociclib in first line: a nation-wide Danish retrospective study

  Alan Celik, Laurits Sebastian Dahl, Rasmus Garly, Vesna Glavicic, Maja Bendtsen Sharma, Sophie Yammeni, Humma Khan, Daniel Sloth Hauberg, Hanne Schultz Kapel, Ann Knoop, Tobias Berg

  778-783

• The promises of precision medicine – voices from the Nordics

  Mef Nilbert

  775-777

• Real-world data on immune checkpoint inhibitors in advanced sarcomas across multiple European institutions

  Stefania Kokkali, Ana Dolcan, Kjetil Boye, Anastasios Kyriazoglou, Ioannis Boukovinas, Foteini Kalofonou, Anna Koumarianou, Natalia Asimakopoulou, Eleftherios Vorrias, Konstantinos Tsapakidis, Eleni Georgaki, Anna Boulouta, Leonidas Mavroeidis, Magnus Harneshaug, Stamatios Theocharis, Robin L. Jones, Antonia Digklia

  761-768

• Feasibility and outcome of genomics-guided treatment selection in advanced cancer – the MEGALiT explorative clinical trial

  Lars Ny, Henrik Fagman, Johan Botling, Loviisa Mantovaara, Peter Asplund, Hannah Karlsson, Jennie Aust, Edvard Abel, Mats Hellström, Joakim Crona, Peter Nygren

  742-750

• Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKI) for optimized outcome in patients with metastatic renal cell carcinoma. The TKI-TDM Trial. Study protocol

  Jakob N. Henriksen, Charlotte U. Andersen, Frede Donskov, Elke Hoffmann-Lücke, Eva Greibe, Niels Fristrup

  729-733

• Hedgehog inhibitors exert anti-proliferation effects and synergistically interact with trastuzumab in HER2-positive gastric cancer models

  Zixin Yang, Ren Niu, Jinzhu Han, Jie Guo, Yingqian Lv

  715-728

• Impact of the risk-adapted Nordic anal cancer group consensus guidelines on the contouring of the elective clinical target volume in anal cancer

  Marcus Johnsson, Sara Alkner, Anders Johnsson, Martin P. Nilsson

  708-714

• European practice on neurovascular late effects after pediatric radiotherapy: considerations on dose planning and follow-up – a HARMONIC/SIOPE ROWG survey

  Laura Toussaint, Louise Tram Henriksen, Karen Van Beek, Stephanie Bolle, Charlotte Demoor-Goldschmidt, Jenny Gains, Morten Høyer, Geert O. Janssens, Rolf-Dieter Kortmann, Catia Martins Pedro, Beate Timmermann, Katrin Scheinemann, Yasmin Lassen-Ramshad

  703-707

• Quantifying the dosimetric impact of online daily adaptation for MR-guided RT in cervical cancer

  Amerah Alshamrani, Robert Chuter, Marianne Aznar, Peter Hoskin, Claire Nelder, Ananya Choudhury, Lisa Barraclough, Cynthia L. Eccles

  693-702

• Simultaneous integrated boost intensity-modulated radiotherapy for treatment of bone metastases: analysis of a breast cancer cohort

  Fabio Marazzi, Valeria Masiello, Alessandra Fabi, Stefania Manfrida, Barbara Corvari, Valentina Lancellotta, Ciro Mazzarella, Silvia Longo, Martina De Angeli, Francesca Moschella, Alba Di Leone, Armando Orlandi, Serena Bracci, Giuseppe Ferdinando Colloca, Mariangela Massaccesi, Luca Boldrini, Luca Tagliaferri, Emilio Bria, Riccardo Masetti, Gianluca Franceschini, Vincenzo Valentini, Maria Antonietta Gambacorta, Francesco Cellini

  685-692

• Dosimetric comparison of intensity-modulated proton therapy and proton arc therapy for pediatric ependymoma

  Helge Henjum, Karoline Mo Feten, Erlend Hartvigsen, Kristian S. Ytre-Hauge, Camilla G. Boer, Camilla H. Stokkevåg

  654-660

• Clinical characteristics and treatment outcome in p16 negative anal cancer

  Catherine Burgos, Calin Radu, Sofia Heyman, Nina Cavalli-Björkman, Peter Nygren

  633-640

• Balancing between A and I

  Emma Skovgaard Pedersen, Christoffer Johansen, Mette Kielsholm Thomsen

  641-643

• Patients with uHCC and Child-Pugh B8/9 also benefit from a combination of antiangiogenic agents and PD-1 inhibitors: a multicenter real-world study

  Xiaoyan Ding, Xue Yin, Linlin Zheng, Lin Zhou, Junke Hu, Wei Sun, Lei Sun, Yanjun Shen, Ying Teng, Yawen Xu, Wendong Li, Mei Liu, Jinglong Chen

  607-615

• Lower MeDiC score is associated with non-referral to multidisciplinary team meeting discussion in bladder cancer patients: a nationwide and population-based study

  Jessica Wihl, Oskar Hagberg, Firas Aljabery, Truls Gårdmark, Abolfazl Hosseini, Staffan Jahnson, Tomas Jerlström, Viveka Ströck, Karin Söderkvist, Anders Ullén, Lars Holmberg, Christel Häggström, Fredrik Liedberg

  616-622

• Pre-treatment tumour PET metrics and clinical outcomes of anal cancer in patients living with and without HIV

  Michael Pennock, N. Patrik Brodin, Christian Velten, Megi Gjini, Nitin Ohri, Chandan Guha, Shalom Kalnicki, Wolfgang A. Tome, Madhur K. Garg, Rafi Kabarriti

  564-573

• The use of pegylated liposomal doxorubicin in metastatic soft tissue sarcoma

  Trang Pham, Hanne Krogh Rose, Philip Rossen, Ninna Aggerholm Pedersen

  558-563

• Treating intrahepatic cholangiocarcinoma with pemigatinib: two case reports of Nordic patients

  Vesa T. Väliaho, Iben Spanggaard

  534-539

• Cardiotoxicity in patients with metastatic melanoma treated with BRAF/MEK inhibitors: a real-world analysis of incidence, risk factors, and reversibility

  Jonas K. Oddershede, Ida K. Meklenborg, Lars Bastholt, Louise M. Guldbrandt, Henrik Schmidt, Rasmus B. Friis

  507-515

• Treatment group-specific inferences in Phase III Randomized Oncology Trials

  Alexander D. Sherry, Adina H. Passy, Joseph Abi Jaoude, Timothy A. Lin, Ramez Kouzy, Pavlos Msaouel, Ethan B. Ludmir

  470-474